700 people. 20 years. 1 medicine. In this episode of Discovery Files, veteran scientists Warren Kati, PhD, and Seble Wagaw detail the exhilarating journey to uncover a treatment for people with HCV.
We are working with the hepatitis C community to support an estimated 300 targeted, local micro-elimination projects worldwide to move us closer to a world free of hepatitis C. These projects are helping fuel new models of care from the prisons of Portugal to the remote mountains of South Korea. These are a select few of the AbbVie efforts being conducted around the world:
Partnering to solve pressing challenges
AbbVie has a long history of working with stakeholders to increase access to our medicines worldwide, including licensing our medicine to quality-assured providers of generics so treatments are available for individuals in more than 90 low- and middle-income countries and territories.
* Patients who achieve a sustained virologic response at 12 weeks post treatment (SVR12) are considered cured of hepatitis C.